Valentina A. Seraya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Valentina A. Seraya has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Elena Yu. Afonina
Sechenov First Moscow State Medical University (Sechenov University)
7 shared publications - Maria N. Nikolaeva
Sechenov First Moscow State Medical University (Sechenov University)
6 shared publications - Yuliya O. Kostina
Sechenov First Moscow State Medical University (Sechenov University)
6 shared publications - Elena S. Zholobova
Sechenov First Moscow State Medical University (Sechenov University)
5 shared publications - Svetlana N. Chebysheva
Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Angelina Polyanskaya
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications
Latest Publications
- Open Access
- 17 October 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 182-191
Towards the differential diagnosis of joint syndrome: Juvenile idiopathic arthritis and joint lesions in inflammatory bowel disease
Introduction. A range of diseases that require differential diagnostic search in persistent joint syndrome in children include juvenile idiopathic arthritis (JIA) and joint lesions in inflammatory bowel diseases (IBD). Aim . To analyze and compare the nature of joint syndrome in children with JIA and Crohn’s disease (CD) with joint lesions. Materials and methods . The joint syndrome was analyzed in a group that included 23 children with JIA and 24 children with Crohn’s disease with joint lesions. Statistical data were processed using parametric tests and exact formulas for percentage-based relationships. Results . JIA typically affected the knee, ankle, hip, and wrist joints (21 (91.3%), 14 (60.9%), 15 (65.2%), and 5 (21.7%) children, respectively). Enthesopathies were detected in 4 (17.4%) children. CD caused spondyloarthritis in 5 children (10.8%) and peripheral joint lesions in 15 patients (58.3%). Knees, hips, and small joints of the hands and feet were affected most frequently (14 (58.3%), 13 (54.2%), 9 (37.5%), and 4 (16.7%) children, respectively). Enthesopathies were detected in 10 children (41.7%). An analysis of the comparative frequency of joint lesions in JIA and CD showed that the knee, ankle, and wrist joints were significantly more often involved in JIA, while enthesitis were significantly more often detected in CD (p < 0.05). 5 patients (10.8%) had CD-associated spondyloarthritis. Antinuclear antibodies were identified significantly more often in patients with JIA (p < 0.05). The article is also illustrated with two clinical case reports. Conclusions . The data presented demonstrate differences in the nature of joint syndrome in children with JIA and CD. A detailed history taking, physical examination, and assessment of the nature of the joint syndrome make it possible to establish a correct diagnosis and select a rational approach to the management of patients.
- 17 October 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 182-191
Open AccessTowards the differential diagnosis of joint syndrome: Juvenile idiopathic arthritis and joint lesions in inflammatory bowel disease
Introduction. A range of diseases that require differential diagnostic search in persistent joint syndrome in children include juvenile idiopathic arthritis (JIA) and joint lesions in inflammatory bowel diseases (IBD). Aim . To analyze and compare the nature of joint syndrome in children with JIA and Crohn’s disease (CD) with joint lesions. Materials and methods . The joint syndrome was analyzed in a group that included 23 children with JIA and 24 children with Crohn’s disease with joint lesions. Statistical data were processed using parametric tests and exact formulas for percentage-based relationships. Results . JIA typically affected the knee, ankle, hip, and wrist joints (21 (91.3%), 14 (60.9%), 15 (65.2%), and 5 (21.7%) children, respectively). Enthesopathies were detected in 4 (17.4%) children. CD caused spondyloarthritis in 5 children (10.8%) and peripheral joint lesions in 15 patients (58.3%). Knees, hips, and small joints of the hands and feet were affected most frequently (14 (58.3%), 13 (54.2%), 9 (37.5%), and 4 (16.7%) children, respectively). Enthesopathies were detected in 10 children (41.7%). An analysis of the comparative frequency of joint lesions in JIA and CD showed that the knee, ankle, and wrist joints were significantly more often involved in JIA, while enthesitis were significantly more often detected in CD (p < 0.05). 5 patients (10.8%) had CD-associated spondyloarthritis. Antinuclear antibodies were identified significantly more often in patients with JIA (p < 0.05). The article is also illustrated with two clinical case reports. Conclusions . The data presented demonstrate differences in the nature of joint syndrome in children with JIA and CD. A detailed history taking, physical examination, and assessment of the nature of the joint syndrome make it possible to establish a correct diagnosis and select a rational approach to the management of patients.
- Open Access
- 4 April 2025
- Published by Consilium Medicum in Pediatrics. Consilium Medicum
- Vol. 1 (1) , 101-109
Challenges in the diagnosis of inflammatory bowel diseases in children: Author's data and a clinical case
Inflammatory bowel diseases (IBD) Crohn's disease (CD) and ulcerative colitis (UC) are a group of idiopathic abnormal bowel conditions with unclear etiology and similar clinical courses. In addition to intestinal syndrome, these diseases are often associated with extraintestinal manifestations, the most common of which is the involvement of the peripheral joints and axial skeleton. The increase in the incidence of IBD, especially CD, in childhood warrants further study of this condition's features, including the most common extraintestinal manifestation: joint involvement (JI) in pediatric patients with IBD. Aim. To analyze the features of JI in CD and UC and the timing of its occurrence associated with IBD onset. Materials and methods. We reviewed 146 case histories of patients aged 4 to 18 diagnosed with CD and UC treated in the Gastroenterological Department and Rheumatological Department No.1 of the Mother and Child Center of Sechenov University from 2017 to 2024. The diagnosis of CD and UC was established following the clinical guidelines of the Union of Pediatricians of Russia for diagnosing and treating CD (2021) and UC (2024) in children. A rheumatologist examined the joints and assessed the JI. The classification criteria of the Assessment of SpondyloArthritis International Society (ASAS, 2011) for predominantly peripheral spondyloarthritis and the Garmisch-Partenkirchen JAS Diagnostic Criteria (1987) were used to verify the cause of the joint involvement. Mean values and standard deviation (M±σ) were used to summarize and estimate demographic continuous variables. Absolute values and percentages were calculated for patients in each study group. Results. Of the 146 patients, 60 (41%) had a combination of JI and IBD. Sixty children aged 4 to 18 with IBD and JI were divided into three groups: 36 (60%) patients with CD, 19 (32%) with UC, and 5 (8%) children with undifferentiated colitis (UndC). The mean age of patients with CD was 14.06±0.5, with UC–13.6±0.3, and UndC–15.2±0.2 years. Among all 60 patients, JI manifested with peripheral arthritis (PA) in 25 (42%) subjects, spondyloarthritis (SpA) in 16 (27%) subjects, or only arthralgias without evident inflammatory changes in the joints in 19 (31%). The analysis of JI variants by groups in children with CD (n=36) showed PA in 15 (42%), SpA in 12 (33%), and isolated arthralgia in 9 (25%) patients. The prevalence of PA and arthralgia among boys and girls with CD was comparable (60 and 40% of PA, 56 and 44% of arthralgias, respectively); the prevalence of SpA in boys with CD was significantly higher: found in 11 (92%) boys. In the group of children with UC (n=19), a high prevalence of PA and isolated arthralgia was reported: 8 (42%) and 9 (47%) patients, respectively. SpA was diagnosed in 2 (11%) children with UC. Of the 60 children with JI and IBD, 30 (50%) developed the disease with joint involvement. CD onset was associated with JI significantly more often than UC onset: of 30 children with JI, 21 (70%) were first diagnosed with rheumatic joint disease, and then CD was detected during follow-up. The disease first manifested with joint involvement in 6 (20%) patients with UC and 3 (10%) with UndC. The time interval from the onset of JI to the onset of the intestinal syndrome (and/or IBD diagnosis) varied widely from 1 month to several years; in 1 patient, it was more than 8 years. In 8 (27%) patients, this time interval was 1 to 3 months; in 6 (20%) patients, the symptoms of the underlying disease appeared within 12 to 24 months from the joint involvement manifestation. The atypical onset and course of the disease make diagnosis challenging and require increased doctor attention to patient management. As an illustration, the article presents a clinical case of an atypical onset and course of CD associated with juvenile SpA.
- 4 April 2025
- Published by Consilium Medicum in Pediatrics. Consilium Medicum
- Vol. 1 (1) , 101-109
Open AccessChallenges in the diagnosis of inflammatory bowel diseases in children: Author's data and a clinical case
Inflammatory bowel diseases (IBD) Crohn's disease (CD) and ulcerative colitis (UC) are a group of idiopathic abnormal bowel conditions with unclear etiology and similar clinical courses. In addition to intestinal syndrome, these diseases are often associated with extraintestinal manifestations, the most common of which is the involvement of the peripheral joints and axial skeleton. The increase in the incidence of IBD, especially CD, in childhood warrants further study of this condition's features, including the most common extraintestinal manifestation: joint involvement (JI) in pediatric patients with IBD. Aim. To analyze the features of JI in CD and UC and the timing of its occurrence associated with IBD onset. Materials and methods. We reviewed 146 case histories of patients aged 4 to 18 diagnosed with CD and UC treated in the Gastroenterological Department and Rheumatological Department No.1 of the Mother and Child Center of Sechenov University from 2017 to 2024. The diagnosis of CD and UC was established following the clinical guidelines of the Union of Pediatricians of Russia for diagnosing and treating CD (2021) and UC (2024) in children. A rheumatologist examined the joints and assessed the JI. The classification criteria of the Assessment of SpondyloArthritis International Society (ASAS, 2011) for predominantly peripheral spondyloarthritis and the Garmisch-Partenkirchen JAS Diagnostic Criteria (1987) were used to verify the cause of the joint involvement. Mean values and standard deviation (M±σ) were used to summarize and estimate demographic continuous variables. Absolute values and percentages were calculated for patients in each study group. Results. Of the 146 patients, 60 (41%) had a combination of JI and IBD. Sixty children aged 4 to 18 with IBD and JI were divided into three groups: 36 (60%) patients with CD, 19 (32%) with UC, and 5 (8%) children with undifferentiated colitis (UndC). The mean age of patients with CD was 14.06±0.5, with UC–13.6±0.3, and UndC–15.2±0.2 years. Among all 60 patients, JI manifested with peripheral arthritis (PA) in 25 (42%) subjects, spondyloarthritis (SpA) in 16 (27%) subjects, or only arthralgias without evident inflammatory changes in the joints in 19 (31%). The analysis of JI variants by groups in children with CD (n=36) showed PA in 15 (42%), SpA in 12 (33%), and isolated arthralgia in 9 (25%) patients. The prevalence of PA and arthralgia among boys and girls with CD was comparable (60 and 40% of PA, 56 and 44% of arthralgias, respectively); the prevalence of SpA in boys with CD was significantly higher: found in 11 (92%) boys. In the group of children with UC (n=19), a high prevalence of PA and isolated arthralgia was reported: 8 (42%) and 9 (47%) patients, respectively. SpA was diagnosed in 2 (11%) children with UC. Of the 60 children with JI and IBD, 30 (50%) developed the disease with joint involvement. CD onset was associated with JI significantly more often than UC onset: of 30 children with JI, 21 (70%) were first diagnosed with rheumatic joint disease, and then CD was detected during follow-up. The disease first manifested with joint involvement in 6 (20%) patients with UC and 3 (10%) with UndC. The time interval from the onset of JI to the onset of the intestinal syndrome (and/or IBD diagnosis) varied widely from 1 month to several years; in 1 patient, it was more than 8 years. In 8 (27%) patients, this time interval was 1 to 3 months; in 6 (20%) patients, the symptoms of the underlying disease appeared within 12 to 24 months from the joint involvement manifestation. The atypical onset and course of the disease make diagnosis challenging and require increased doctor attention to patient management. As an illustration, the article presents a clinical case of an atypical onset and course of CD associated with juvenile SpA.
- 6 March 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (1) , 75-81
Efficacy and safety of secukinumab (Cosentyx) in patients with juvenile psoriatic arthritis
Psoriatic arthritis is a chronic inflammatory disease of the peripheral joints, spinal joints and entheses, occurring in 10–25% of patients with psoriasis. Juvenile psoriatic arthritis is classified as a subtype of juvenile idiopathic arthritis. Treatment of juvenile psoriatic arthritis is challenging. One of the main difficulties is that the drugs used in adult patients have restrictions for use in pediatric practice, which limits the available therapeutic options. There are few studies assessing the effectiveness and safety of secakinumab therapy in pediatric practice.Objective. To evaluate the effectiveness and safety of secukinumab (Cosentyx) therapy in children with juvenile psoriatic arthritis in real clinical practice.Methods. The effectiveness of therapy was assessed using the “pediatric” criteria of the American College of Rheumatology (ACRpedi) after 6, 12 and 18 months from the date of administration of secuquinumab (Cosentyx) therapy in 8 patients with jPsA. The main criterion for treatment effectiveness was the achievement of at least 50% (ACR pedi 50) improvement. To assess the area and severity of skin manifestations of psoriasis, the PASI (Psoriasis Area Severity Index) index was used. To assess the area of skin affected by psoriatic rashes, the body surface area index (BSA) was used.Results. By the 6th month of therapy with secukinumab (Cosentyx), a general assessment of the effectiveness of treatment was completed in all children (n-8): ACRpedi50 in 1 (12.5%), ACRpedi70 in 3 (37.5%); ACRpedi90/100 in 4 (50%). By the 12th month of therapy with secukinumab (Cosentyx), according to a comprehensive assessment of the effectiveness of therapy, all remaining children (n-5) responded to treatment: ACRpedi70/90/100 were 60/60/60%. Inactive disease status was achieved in 60% of cases. By the 18th month from the start of therapy, ACRpedi was assessed in 5 children: ACRpedi 70/90/100 were 60/60/60%, respectively. In 3 patients from the initial number of children, pharmacological clinical and laboratory remission of the disease was achieved by the 18th month of therapy.
- 6 March 2025
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 70 (1) , 75-81
Efficacy and safety of secukinumab (Cosentyx) in patients with juvenile psoriatic arthritis
Psoriatic arthritis is a chronic inflammatory disease of the peripheral joints, spinal joints and entheses, occurring in 10–25% of patients with psoriasis. Juvenile psoriatic arthritis is classified as a subtype of juvenile idiopathic arthritis. Treatment of juvenile psoriatic arthritis is challenging. One of the main difficulties is that the drugs used in adult patients have restrictions for use in pediatric practice, which limits the available therapeutic options. There are few studies assessing the effectiveness and safety of secakinumab therapy in pediatric practice.Objective. To evaluate the effectiveness and safety of secukinumab (Cosentyx) therapy in children with juvenile psoriatic arthritis in real clinical practice.Methods. The effectiveness of therapy was assessed using the “pediatric” criteria of the American College of Rheumatology (ACRpedi) after 6, 12 and 18 months from the date of administration of secuquinumab (Cosentyx) therapy in 8 patients with jPsA. The main criterion for treatment effectiveness was the achievement of at least 50% (ACR pedi 50) improvement. To assess the area and severity of skin manifestations of psoriasis, the PASI (Psoriasis Area Severity Index) index was used. To assess the area of skin affected by psoriatic rashes, the body surface area index (BSA) was used.Results. By the 6th month of therapy with secukinumab (Cosentyx), a general assessment of the effectiveness of treatment was completed in all children (n-8): ACRpedi50 in 1 (12.5%), ACRpedi70 in 3 (37.5%); ACRpedi90/100 in 4 (50%). By the 12th month of therapy with secukinumab (Cosentyx), according to a comprehensive assessment of the effectiveness of therapy, all remaining children (n-5) responded to treatment: ACRpedi70/90/100 were 60/60/60%. Inactive disease status was achieved in 60% of cases. By the 18th month from the start of therapy, ACRpedi was assessed in 5 children: ACRpedi 70/90/100 were 60/60/60%, respectively. In 3 patients from the initial number of children, pharmacological clinical and laboratory remission of the disease was achieved by the 18th month of therapy.
- 1 January 2025
- Published by Dynasty Publishing House in Voprosy praktičeskoj pediatrii
- Vol. 20 (3)
Clinical and immunological manifestations of systemic scleroderma in children according to data from a rheumatology center
A retrospective study contains clinical and immunological characteristics of juvenile systemic scleroderma manifestations in 78 children according to data from a single rheumatology center. The average age of onset was 8.3 years, girls outnumbered boys, the form with diffuse skin involvement was more common, and among visceral involvement, the gastrointestinal tract and lungs were the most commonly affected; antinuclear factor was detected in 81% of children, anticentromere antibodies in 31%, and antitopoisomerase antibodies in 8.5%. The 5-year survival rate of patients in the main group was 100%, and the probability of survival at 74 months was 70%. Our data largely coincide with the studies of other authors. No obvious natural pathomorphosis of juvenile systemic scleroderma has been established in the 2000s compared to 1960–1980; therapeutic pathomorphosis of the disease is likely to occur. Key words: pathomorphosis, age of onset, visceral involvement, autoantibodies, survival
- 1 January 2025
- Published by Dynasty Publishing House in Voprosy praktičeskoj pediatrii
- Vol. 20 (3)
Clinical and immunological manifestations of systemic scleroderma in children according to data from a rheumatology center
A retrospective study contains clinical and immunological characteristics of juvenile systemic scleroderma manifestations in 78 children according to data from a single rheumatology center. The average age of onset was 8.3 years, girls outnumbered boys, the form with diffuse skin involvement was more common, and among visceral involvement, the gastrointestinal tract and lungs were the most commonly affected; antinuclear factor was detected in 81% of children, anticentromere antibodies in 31%, and antitopoisomerase antibodies in 8.5%. The 5-year survival rate of patients in the main group was 100%, and the probability of survival at 74 months was 70%. Our data largely coincide with the studies of other authors. No obvious natural pathomorphosis of juvenile systemic scleroderma has been established in the 2000s compared to 1960–1980; therapeutic pathomorphosis of the disease is likely to occur. Key words: pathomorphosis, age of onset, visceral involvement, autoantibodies, survival
- 11 April 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (2)
PECULIARITIES OF THE COURSE OF IgG4-RELATED DISEASE IN CHILDREN
- 11 April 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (2)
PECULIARITIES OF THE COURSE OF IgG4-RELATED DISEASE IN CHILDREN
- Open Access
- 15 August 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (8) , 530-534
Inflammatory bowel disease in patients with systemic juvenile arthritis: Case report
Systemic juvenile idiopathic arthritis (SJIA) accounts for 10–15% of juvenile arthritis cases. The incidence of inflammatory bowel disease (IBD) is generally higher in SJIA patients than in the general pediatric population; however, the association of IBD with SJIA is rare. Among 65 patients with SJIA managed in two pediatric rheumatology centers, IBD was detected in 3 patients 3, 8, and 10 years from the SJIA onset. The clinical presentation of IBD in patients with SJIA is rather scanty; the diagnosis is mainly based on the colonoscopy and biopsy results. In 2 patients, Crohn's disease was diagnosed, and undifferentiated colitis in 1 patient.
- 15 August 2023
- Published by Consilium Medicum in Consilium Medicum
- Vol. 25 (8) , 530-534
Open AccessInflammatory bowel disease in patients with systemic juvenile arthritis: Case report
Systemic juvenile idiopathic arthritis (SJIA) accounts for 10–15% of juvenile arthritis cases. The incidence of inflammatory bowel disease (IBD) is generally higher in SJIA patients than in the general pediatric population; however, the association of IBD with SJIA is rare. Among 65 patients with SJIA managed in two pediatric rheumatology centers, IBD was detected in 3 patients 3, 8, and 10 years from the SJIA onset. The clinical presentation of IBD in patients with SJIA is rather scanty; the diagnosis is mainly based on the colonoscopy and biopsy results. In 2 patients, Crohn's disease was diagnosed, and undifferentiated colitis in 1 patient.
- 11 October 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (5)
EXPERIENCE OF USING TOCILIZUMAB IN THERAPY OF TAKAYASU ARTERITIS IN CHILDREN
The prognosis of Takayasu arteritis (TA) depends on timely and adequate therapy, but in about half of patients, the disease is refractory to standard therapy or recurs against the background of a decrease in the dose of glucocorticoids (GCs). The use of biological disease-modifying antirheumatic drugs (bDMARDs) in the treatment of TA looks promising, however, the experience of their use in TA in children is presented by isolated observations. Objective of the study: to evaluate the efficacy and safety of tocilizumab (TCZ) in the treatment of refractory and recurrent forms of TA in children. Materials and methods of research: the study retrospectively included 9 children who were prescribed TCZ when standard therapy was ineffective. Before starting TCZ therapy, all patients were diagnosed with an active form of the disease. The median duration of TCZ therapy was 24 months. Results: against the background of TCZ therapy, the median ESR decreased from 22 to 5 mm/h (p value <0,01), the level of C-reactive protein from 6 to 0 mg/l (p value <0,025). All patients achieved remission. No relapses were observed. The median GCs dose decreased from 0,377 to 0,15 mg/kg/day for prednisolone, 2 patients with GCs were completely canceled. The ITAS.A activity index decreased from 3–12 (median 7) to 0 in 7 and to 1 in 2 more patients. The drug was well tolerated. Adverse reactions included one case of pityriasis versicolor and one case of postoperative phlegmon of the neck and subclavian region on the right. Conclusion: TCZ has shown efficacy and safety for the induction and maintenance of remission in children with TA. The presented results of the study indicate the prospects for further study of the use of TCZ for TA in pediatric practice.
- 11 October 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (5)
EXPERIENCE OF USING TOCILIZUMAB IN THERAPY OF TAKAYASU ARTERITIS IN CHILDREN
The prognosis of Takayasu arteritis (TA) depends on timely and adequate therapy, but in about half of patients, the disease is refractory to standard therapy or recurs against the background of a decrease in the dose of glucocorticoids (GCs). The use of biological disease-modifying antirheumatic drugs (bDMARDs) in the treatment of TA looks promising, however, the experience of their use in TA in children is presented by isolated observations. Objective of the study: to evaluate the efficacy and safety of tocilizumab (TCZ) in the treatment of refractory and recurrent forms of TA in children. Materials and methods of research: the study retrospectively included 9 children who were prescribed TCZ when standard therapy was ineffective. Before starting TCZ therapy, all patients were diagnosed with an active form of the disease. The median duration of TCZ therapy was 24 months. Results: against the background of TCZ therapy, the median ESR decreased from 22 to 5 mm/h (p value <0,01), the level of C-reactive protein from 6 to 0 mg/l (p value <0,025). All patients achieved remission. No relapses were observed. The median GCs dose decreased from 0,377 to 0,15 mg/kg/day for prednisolone, 2 patients with GCs were completely canceled. The ITAS.A activity index decreased from 3–12 (median 7) to 0 in 7 and to 1 in 2 more patients. The drug was well tolerated. Adverse reactions included one case of pityriasis versicolor and one case of postoperative phlegmon of the neck and subclavian region on the right. Conclusion: TCZ has shown efficacy and safety for the induction and maintenance of remission in children with TA. The presented results of the study indicate the prospects for further study of the use of TCZ for TA in pediatric practice.
- Open Access
- 15 May 2019
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 64 (2) , 30-37
Uveitis associated with juvenile idiopathic arthritis
Rheumatoid uveitis is a serious problem in rheumatology and ophthalmology due to the peculiarities of the disease – an undistinguished beginning, chronic course and a high incidence of disabling complications. The article analyzes various data on the development and nature of uveitis in children with juvenile idiopathic arthritis. The authors describe the analysis of the results of various studies of this disease. They consider the features and results of treatment of children with rheumatoid uveitis using genetically engineered biological drugs.
- 15 May 2019
- Published by The National Academy of Pediatric Science and Innovation in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
- Vol. 64 (2) , 30-37
Open AccessUveitis associated with juvenile idiopathic arthritis
Rheumatoid uveitis is a serious problem in rheumatology and ophthalmology due to the peculiarities of the disease – an undistinguished beginning, chronic course and a high incidence of disabling complications. The article analyzes various data on the development and nature of uveitis in children with juvenile idiopathic arthritis. The authors describe the analysis of the results of various studies of this disease. They consider the features and results of treatment of children with rheumatoid uveitis using genetically engineered biological drugs.